Y Intercept Hong Kong Ltd Grows Position in Pfizer Inc. $PFE

Y Intercept Hong Kong Ltd boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 146.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 299,137 shares of the biopharmaceutical company’s stock after purchasing an additional 177,627 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Pfizer were worth $8,400,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Vermillion Wealth Management Inc. increased its holdings in shares of Pfizer by 19.4% during the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares during the last quarter. Triad Wealth Partners LLC boosted its holdings in Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 386 shares during the last quarter. Eagle Capital Management LLC boosted its holdings in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock valued at $3,554,000 after acquiring an additional 390 shares during the last quarter. ETF Store Inc. grew its position in Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after acquiring an additional 396 shares during the period. Finally, Mattern Wealth Management LLC increased its stake in Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on PFE shares. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. UBS Group reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, May 27th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Finally, Bank of America decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.82.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.29 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The company has a market capitalization of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35. The business has a 50-day moving average of $25.63 and a 200-day moving average of $26.23.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.